Qpct Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glutaminyl Cyclase (QPCT) is a gene encoding a crucial enzyme involved in the post-translational modification of proteins. The enzyme catalyzes the conversion of N-terminal glutamine residues to pyroglutamate (pGlu), a modification that significantly alters protein properties and is highly relevant to neurodegenerative disease research.
| Property | Value |
|---|---|
| Symbol | QPCT |
| Full Name | Glutaminyl Cyclase |
| Aliases | QC, GCPII, GCPIII |
| Chromosomal Location | 2p22.2 |
| Gene ID (NCBI) | 25788 |
| HGNC ID | 18329 |
| Ensembl ID | ENSG00000125827 |
| UniProt ID | Q96KH6 |
| Category | Enzyme |
The QPCT-encoded protein, also known as glutaminyl cyclase (QC), is a 360-amino acid enzyme that belongs to the family of metal-dependent hydrolases. QPCT is localized primarily in the Golgi apparatus and extracellular space, where it performs its enzymatic function of converting N-terminal glutamine to pyroglutamate [1]. This modification, known as pyroglutamylation, protects proteins from degradation by aminopeptidases and can dramatically increase the aggregation propensity of certain proteins.
Glutaminyl cyclase catalyzes the intramolecular cyclization of N-terminal glutamine residues to form pyroglutamate (pGlu) residues. This reaction occurs spontaneously under physiological conditions but is dramatically accelerated by QPCT [1]. The enzyme shows specificity for glutamine at the N-terminus, with much slower activity toward glutamate, which forms pyroglutamate through a different mechanism.
The pyroglutamate modification has several important biological consequences:
QPCT has emerged as a significant therapeutic target in Alzheimer's disease (AD). The pyroglutamate-modified amyloid-beta (pE3-Aβ) species is one of the most aggregation-prone and toxic forms of Aβ found in amyloid plaques [3][5]. Key points include:
While less characterized than in AD, QPCT may play a role in ALS through its involvement in protein quality control mechanisms. The enzyme's activity may contribute to the aggregation of TDP-43 and other ALS-associated proteins [8].
QPCT shows widespread expression in the human body, with notable levels in:
Expression is particularly elevated in regions associated with amyloid pathology in AD brains [4].
The development of QPCT inhibitors represents an active area of AD drug discovery:
| Compound | Development Status | Key Features |
|---|---|---|
| PQ912 | Phase 2a clinical trial | First-in-class QC inhibitor |
| PBD150 | Preclinical | High potency in vivo |
| compound 5 | Preclinical | Brain-penetrant |
QPCT inhibitors work by:
The QPCT gene encodes glutaminyl cyclase, an enzyme critical for the formation of pyroglutamate-modified proteins. Its role in generating toxic pE3-Aβ species makes it a compelling therapeutic target in Alzheimer's disease. QPCT inhibitors represent a promising approach to modifying disease progression in AD and potentially other neurodegenerative conditions characterized by protein aggregation.
The study of Qpct Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.